Skip to main

Zhen Chen, PhD

${headerImageAssetTitle}

Biography

Zhen Chen, PhD, is an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A cancer biologist, Dr. Chen is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute.

Education

Dr. Chen earned his PhD in pharmaceutical engineering and technology from Jiangnan University in China. He completed his postdoctoral fellowship at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Titles & Roles

  • Assistant Professor, Department of Hematology and Medical Oncology
    Emory University School of Medicine

Research

Dr. Chen's research interest is to identify promising cancer therapeutic targets and develop efficacious cancer therapeutic drugs or regimens through understanding the biology, particularly survival and death mechanisms of cancer cells. His earlier research work focused on the molecular identity of cellular calcium homeostasis, tumor differentiation, tumor progression, metastasis, multi-drug resistance, blood pressure regulation and intervention strategies.

Publications

Title/Journal Authors Publication Date

Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells.

Oncogene

 YT Oh, Z Chen, D Wang, SS Ramalingam, SY Sun 04/17/2025

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.

The Journal of experimental medicine

 Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun 11/04/2024

Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

 Z Chen, KA Vallega, VK Boda, Z Quan, D Wang, S Fan, Q Wang, SS Ramalingam, W Li, SY Sun 09/01/2024

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.

The Journal of clinical investigation

 Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun 03/07/2024

The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.

Pharmacological research

 Z Chen, KA Vallega, H Chen, J Zhou, SS Ramalingam, SY Sun 01/01/2022

Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.

Oncogene

 Z Chen, D Yu, TK Owonikoko, SS Ramalingam, SY Sun 12/01/2021

Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.

Cancer letters

 W Zhao, D Yu, Z Chen, W Yao, J Yang, SS Ramalingam, SY Sun 10/28/2021

Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.

Molecular cancer research : MCR

 G Qian, J Guo, KA Vallega, C Hu, Z Chen, Y Deng, Q Wang, S Fan, SS Ramalingam, TK Owonikoko, W Wei, SY Sun 10/01/2021

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.

Cancer research

 L Zhu, Z Chen, H Zang, S Fan, J Gu, G Zhang, KD Sun, Q Wang, Y He, TK Owonikoko, SS Ramalingam, SY Sun 09/15/2021

Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli.

Apoptosis : an international journal on programmed cell death

 L Zhao, L Zhu, YT Oh, G Qian, Z Chen, SY Sun 06/01/2021

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.

Theranostics

 S Zhang, Z Chen, P Shi, S Fan, Y He, Q Wang, Y Li, SS Ramalingam, TK Owonikoko, SY Sun 01/01/2021

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.

American journal of cancer research

 D Yu, Y Li, KD Sun, J Gu, Z Chen, TK Owonikoko, SS Ramalingam, SY Sun 01/01/2020